Please Wait.....
Report
Global Cardiac Biomarker Testing Market Report and Forecast 2024-2032
Market Report I 2023-09-18 I 140 Pages I EMR Inc.
Global Cardiac Biomarker Testing Market Report and Forecast 2024-2032
Global Cardiac Biomarker Testing Market Outlook
The global cardiac biomarker testing market size was valued at USD 4.7 billion in 2023, driven by the increasing prevalence of cardiovascular diseases across the globe. The market size is anticipated to grow at a CAGR of 8.8% during the forecast period of 2024-2032 to achieve a value of USD 10 billion by 2032.
Cardiac Biomarker Testing: Introduction
Cardiac biomarker testing, also known as cardiac marker testing, refers to the measurement of specific substances or molecules in the blood that are released into the bloodstream when there is damage to the heart or its muscles. These biomarkers play a crucial role in the diagnosis, risk assessment, and management of various cardiac conditions, including heart attacks (myocardial infarctions), heart failure, and other cardiovascular diseases. Cardiac biomarker testing provides valuable information to healthcare professionals for timely intervention and patient care. Some common cardiac biomarkers include:
- Troponin: Troponin is one of the most sensitive and specific cardiac biomarkers. It is released into the bloodstream when there is damage to the heart muscle, such as during a heart attack. Troponin levels rise within hours of cardiac injury and remain elevated for several days.
- Creatine Kinase-MB (CK-MB): CK-MB is an enzyme found predominantly in heart muscle cells. Elevated CK-MB levels indicate heart muscle damage and are often used in conjunction with troponin measurements to confirm a heart attack.
- Myoglobin: Myoglobin is a protein found in heart and skeletal muscles. It is a less specific cardiac biomarker compared to troponin and CK-MB, but elevated myoglobin levels can suggest heart muscle damage.
Key Trends in the Global Cardiac Biomarker Testing Market
Here are some key trends in the market:
- The field of cardiac biomarker testing continues to evolve with advancements in technology, changes in healthcare practices, and an emphasis on early diagnosis and precision medicine. As of my last knowledge update in September 2021, here are some notable trends in the cardiac biomarker testing market:
- High-Sensitivity Cardiac Troponin Assays: High-sensitivity cardiac troponin assays are becoming more widespread. These assays can detect even minor elevations in troponin levels, enabling earlier diagnosis of acute myocardial infarction (heart attack) and improved risk assessment.
- Multi-Biomarker Panels: Rather than relying solely on a single biomarker, healthcare providers are increasingly using multi-biomarker panels. Combining different cardiac biomarkers provides a more comprehensive picture of a patient's cardiac health and can enhance diagnostic accuracy.
- Point-of-Care Testing (POCT): Point-of-care cardiac biomarker testing is gaining popularity for rapid assessment of cardiac conditions in emergency departments and ambulances. POCT devices allow for faster decision-making and triage of patients with chest pain or suspected heart attacks.
- Personalized Medicine: The concept of personalized medicine is extending to cardiac biomarker testing. Genetic factors and individual patient profiles are increasingly considered when interpreting biomarker results and tailoring treatment plans.
- Use of Artificial Intelligence (AI): AI and machine learning algorithms are being employed to analyze complex biomarker data, predict cardiac events, and assist in risk stratification. These technologies can enhance the precision of diagnosis and treatment decisions.
- Expanded Clinical Applications: Beyond diagnosing heart attacks and heart failure, cardiac biomarker testing is finding applications in predicting and monitoring other cardiovascular conditions, such as atrial fibrillation, cardiac arrhythmias, and valvular heart disease.
Global Cardiac Biomarker Testing Market Segmentations
The market can be categorized into testing type, technology, biomarker type, applications, end user, and region.
Market Breakup by Testing Type
- Point of Care Testing (POCT)
- Laboratory Testing
Market Breakup by Technology
- Immunoassay
- Clinical Chemistry
- Molecular Diagnostics
- Others
Market Breakup by Biomarker Type
- Creatine Kinase (CK-MB)
- Troponins
- Myoglobin
- Natriuretic Peptides (BNP and NT-proBNP)
- Ischemia Modified Albumins
- Other Biomarkers
Market Breakup by Applications
- Myocardial Infraction
- Congestive Heart Failure
- Acute Coronary Syndrome
- Atherosclerosis
- Other Applications
Market Breakup by End User
- Hospitals and Clinics
- Diagnostic Laboratories
- Ambulatory Surgical Centres
- Research Institutes
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Cardiac Biomarker Testing Market Overview
Here are some key drivers for the cardiac biomarker testing market:
- Rising Cardiovascular Disease Burden: Cardiovascular diseases, including coronary artery disease, heart failure, and arrhythmias, continue to be a leading cause of morbidity and mortality globally. The increasing prevalence of these conditions drives the demand for cardiac biomarker testing for early diagnosis and management.
- Aging Population: The aging demographic trend results in a higher incidence of heart-related conditions, making cardiac biomarker testing essential for the elderly population.
- Preventive Medicine: There is a growing emphasis on preventive healthcare, and cardiac biomarker testing plays a role in identifying individuals at risk of developing cardiovascular diseases, allowing for early intervention and lifestyle modifications.
- Technological Advancements: Ongoing advancements in biomarker assay technologies, including high-sensitivity assays, enable more accurate and earlier detection of cardiac biomarkers, improving diagnostic capabilities.
- Point-of-Care Testing (POCT): The availability of point-of-care cardiac biomarker testing devices allows for rapid assessment and triage of patients in emergency departments and ambulances, leading to quicker treatment decisions.
- Personalized Medicine: Cardiac biomarker testing is increasingly used to tailor treatment plans to individual patient profiles, including genetic factors and biomarker levels, optimizing therapy and outcomes.
Cardiac Biomarker Testing Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd.
- Siemens Healthineers AG
- Beckman Coulter, Inc. (Danaher Corporation)
- bioMerieux SA
- Ortho Clinical Diagnostics
- Becton, Dickinson and Company (BD)
- Thermo Fisher Scientific Inc.
- Randox Laboratories Ltd.
- Bio-Rad Laboratories, Inc.
- Singulex Inc.
- Abbott
- LSI Medience Corporation
- Trivitron Healthcare
- Qingdao Rich Biotechnology Co., Ltd.
- Werfen
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- Guangzhou Wondfo Biotech Co., Ltd.
- Abnova Corporation
- Merck KGaA
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.
1Preface
1.1Objectives of the Study
1.2Key Assumptions
1.3Report Coverage - Key Segmentation and Scope
1.4Research Methodology
2Executive Summary
3Global Cardiac Biomarker Testing Market Overview
3.1Global Cardiac Biomarker Testing Market Historical Value (2017-2023)
3.2Global Cardiac Biomarker Testing Market Forecast Value (2024-2032)
4Global Cardiac Biomarker Testing Market Landscape
4.1Global Cardiac Biomarker Testing Developers Landscape
4.1.1Analysis by Year of Establishment
4.1.2Analysis by Company Size
4.1.3Analysis by Region
4.2Global Cardiac Biomarker Testing Product Landscape
4.2.1Analysis by Type
4.2.2Analysis by Technology
4.2.3Analysis by Applications
5Global Cardiac Biomarker Testing Market Dynamics
5.1Market Drivers and Constraints
5.2SWOT Analysis
5.3Porter's Five Forces Model
5.4Key Demand Indicators
5.5Key Price Indicators
5.6Industry Events, Initiatives, and Trends
5.7Value Chain Analysis
6Global Cardiac Biomarker Testing Market Segmentation
6.1Global Cardiac Biomarker Testing Market by Testing Type
6.1.1Market Overview
6.1.2Point of Care Testing (POCT)
6.1.3Laboratory Testing
6.2Global Cardiac Biomarker Testing Market by Technology
6.2.1Market Overview
6.2.2Immunoassay
6.2.3Clinical Chemistry
6.2.4Molecular Diagnostics
6.2.5Others
6.3Global Cardiac Biomarker Testing Market by Biomarker Type
6.3.1Market Overview
6.3.2Creatine Kinase (CK-MB)
6.3.3Troponins
6.3.4Myoglobin
6.3.5Natriuretic Peptides (BNP and NT-proBNP)
6.3.6Ischemia Modified Albumins
6.3.7Other Biomarkers
6.4Global Cardiac Biomarker Testing Market by Applications
6.4.1Market Overview
6.4.2Myocardial Infraction
6.4.3Congestive Heart Failure
6.4.4Acute Coronary Syndrome
6.4.5Atherosclerosis
6.4.6Other Applications
6.5Global Cardiac Biomarker Testing Market by End User
6.5.1Market Overview
6.5.2Hospitals and Clinics
6.5.3Diagnostic Laboratories
6.5.4Ambulatory Surgical Centers
6.5.5Research Institutes
6.5.6Others
6.6Global Cardiac Biomarker Testing Market by Region
6.6.1Market Overview
6.6.2North America
6.6.3Europe
6.6.4Asia Pacific
6.6.5Latin America
6.6.6Middle East and Africa
7North America Cardiac Biomarker Testing Market
7.1Market Share by Country
7.2United States of America
7.3Canada
8Europe Cardiac Biomarker Testing Market
8.1Market Share by Country
8.2United Kingdom
8.3Germany
8.4France
8.5Italy
8.6Others
9Asia Pacific Cardiac Biomarker Testing Market
9.1Market Share by Country
9.2China
9.3Japan
9.4India
9.5ASEAN
9.6Australia
9.7Others
10Latin America Cardiac Biomarker Testing Market
10.1Market Share by Country
10.2Brazil
10.3Argentina
10.4Mexico
10.5Others
11Middle East and Africa Cardiac Biomarker Testing Market
11.1Market Share by Country
11.2Saudi Arabia
11.3United Arab Emirates
11.4Nigeria
11.5South Africa
11.6Others
12Patent Analysis
12.1Analysis by Type of Patent
12.2Analysis by Publication year
12.3Analysis by Issuing Authority
12.4Analysis by Patent Age
12.5Analysis by CPC Analysis
12.6Analysis by Patent Valuation
12.7Analysis by Key Players
13Grants Analysis
13.1Analysis by year
13.2Analysis by Amount Awarded
13.3Analysis by Issuing Authority
13.4Analysis by Grant Application
13.5Analysis by Funding Institute
13.6Analysis by NIH Departments
13.7Analysis by Recipient Organization
14Funding Analysis
14.1Analysis by Funding Instances
14.2Analysis by Type of Funding
14.3Analysis by Funding Amount
14.4Analysis by Leading Players
14.5Analysis by Leading Investors
14.6Analysis by Geography
15Partnership and Collaborations Analysis
15.1Analysis by Partnership Instances
15.2Analysis by Type of Partnership
15.3Analysis by Leading Players
15.4Analysis by Geography
16Regulatory Framework
16.1Regulatory Overview
16.1.1US FDA
16.1.2EU EMA
16.1.3INDIA CDSCO
16.1.4JAPAN PMDA
16.1.5Others
17Supplier Landscape
17.1Abbott Laboratories
17.1.1Financial Analysis
17.1.2Product Portfolio
17.1.3Demographic Reach and Achievements
17.1.4Mergers and Acquisition
17.1.5Certifications
17.2F. Hoffmann-La Roche Ltd.
17.2.1Financial Analysis
17.2.2Product Portfolio
17.2.3Demographic Reach and Achievements
17.2.4Mergers and Acquisition
17.2.5Certifications
17.3Siemens Healthineers AG
17.3.1Financial Analysis
17.3.2Product Portfolio
17.3.3Demographic Reach and Achievements
17.3.4Mergers and Acquisition
17.3.5Certifications
17.4Beckman Coulter, Inc. (Danaher Corporation)
17.4.1Financial Analysis
17.4.2Product Portfolio
17.4.3Demographic Reach and Achievements
17.4.4Mergers and Acquisition
17.4.5Certifications
17.5bioMerieux SA
17.5.1Financial Analysis
17.5.2Product Portfolio
17.5.3Demographic Reach and Achievements
17.5.4Mergers and Acquisition
17.5.5Certifications
17.6Ortho Clinical Diagnostics
17.6.1Financial Analysis
17.6.2Product Portfolio
17.6.3Demographic Reach and Achievements
17.6.4Mergers and Acquisition
17.6.5Certifications
17.7Becton, Dickinson and Company (BD)
17.7.1Financial Analysis
17.7.2Product Portfolio
17.7.3Demographic Reach and Achievements
17.7.4Mergers and Acquisition
17.7.5Certifications
17.8Thermo Fisher Scientific Inc.
17.8.1Financial Analysis
17.8.2Product Portfolio
17.8.3Demographic Reach and Achievements
17.8.4Mergers and Acquisition
17.8.5Certifications
17.9Randox Laboratories Ltd.
17.9.1Financial Analysis
17.9.2Product Portfolio
17.9.3Demographic Reach and Achievements
17.9.4Mergers and Acquisition
17.9.5Certifications
17.10Bio-Rad Laboratories, Inc.
17.10.1Financial Analysis
17.10.2Product Portfolio
17.10.3Demographic Reach and Achievements
17.10.4Mergers and Acquisition
17.10.5Certifications
17.11Singulex Inc.
17.11.1Financial Analysis
17.11.2Product Portfolio
17.11.3Demographic Reach and Achievements
17.11.4Mergers and Acquisition
17.11.5Certifications
17.12Abbott
17.12.1Financial Analysis
17.12.2Product Portfolio
17.12.3Demographic Reach and Achievements
17.12.4Mergers and Acquisition
17.12.5Certifications
17.13LSI Medience Corporation
17.13.1Financial Analysis
17.13.2Product Portfolio
17.13.3Demographic Reach and Achievements
17.13.4Mergers and Acquisition
17.13.5Certifications
17.14Trivitron Healthcare
17.14.1Financial Analysis
17.14.2Product Portfolio
17.14.3Demographic Reach and Achievements
17.14.4Mergers and Acquisition
17.14.5Certifications
17.15Qingdao Rich Biotechnology Co., Ltd.
17.15.1Financial Analysis
17.15.2Product Portfolio
17.15.3Demographic Reach and Achievements
17.15.4Mergers and Acquisition
17.15.5Certifications
17.16Werfen
17.16.1Financial Analysis
17.16.2Product Portfolio
17.16.3Demographic Reach and Achievements
17.16.4Mergers and Acquisition
17.16.5Certifications
17.17Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
17.17.1Financial Analysis
17.17.2Product Portfolio
17.17.3Demographic Reach and Achievements
17.17.4Mergers and Acquisition
17.17.5Certifications
17.18Guangzhou Wondfo Biotech Co., Ltd.
17.18.1Financial Analysis
17.18.2Product Portfolio
17.18.3Demographic Reach and Achievements
17.18.4Mergers and Acquisition
17.18.5Certifications
17.19Abnova Corporation
17.19.1Financial Analysis
17.19.2Product Portfolio
17.19.3Demographic Reach and Achievements
17.19.4Mergers and Acquisition
17.19.5Certifications
17.20Merck KGaA
17.20.1Financial Analysis
17.20.2Product Portfolio
17.20.3Demographic Reach and Achievements
17.20.4Mergers and Acquisition
17.20.5Certifications
18Global Cardiac Biomarker Testing Market - Distribution Model (Additional Insight)
18.1Overview
18.2Potential Distributors
18.3Key Parameters for Distribution Partner Assessment
19Key Opinion Leaders (KOL) Insights (Additional Insight)
20Company Competitiveness Analysis (Additional Insight)
20.1Very Small Companies
20.2Small Companies
20.3Mid-Sized Companies
20.4Large Companies
20.5Very Large Companies
21Payment Methods (Additional Insight)
21.1Government Funded
21.2Private Insurance
21.3Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security